---

Where things actually stand

On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee - PCAC - met at the agency's White Oak campus to consider seven peptide-related bulk drug substances for the Section 503A Bulks List. The committee recommended six of them, in both free-base and acetate forms, and declined to recommend emideltide, better known as DSIP.

The votes were narrow, and they broke against the agency's own scientists. FDA staff had proposed that none of the fourteen peptide forms under review be included. The committee recommended six anyway. Observers in the room described an audible reaction when the first tally was read, because a PCAC panel voting against FDA staff's written recommendation is close to unprecedented.

Here is what that vote did not do:

• It did not approve any peptide as a drug.
• It did not place anything in Category 1.
• It did not add anything to the 503A Bulks List. The six substances are not in 21 CFR 216.23.
• It did not authorize a single compounding pharmacy to prepare any of them.

PCAC advises. FDA decides. Adding a substance to the Bulks List requires notice-and-comment rulemaking - a proposed rule, a public comment window, agency review of the comments, then a final rule. Based on how prior 503A cycles have run, that is realistically a matter of many months, not weeks, and FDA is not obligated to adopt any recommendation its advisory committee makes.

If you have seen a claim that these six peptides are now legal, that claim is wrong.

The part almost nobody is covering

The July meeting was the first round, not the last one. FDA has indicated it intends to bring a second group of peptide substances before the committee at a meeting expected before the end of February. The compounds named in that group are:

LL-37 - A human cathelicidin-derived antimicrobial peptide. It is one of the more heavily published compounds in the group, largely in innate-immunity and antimicrobial literature.

GHK-Cu - The copper tripeptide. Among the most-searched peptides in the entire category, driven substantially by topical and cosmetic interest rather than the injectable form under regulatory review. Worth noting that the injectable form is what the regulatory conversation concerns; the two are frequently conflated in consumer coverage.

Dihexa acetate - An angiotensin IV analog studied in neurotrophic models. Thin literature relative to the others, and characterization questions have followed it.

Melanotan II - A synthetic melanocortin analog. Search interest has climbed steeply, but it carries the most explicit safety record in the group: the UK's MHRA has publicly warned against its use, citing nausea, blood-pressure effects and melanoma risk. Regulators on both sides of the Atlantic have been consistent about this one.

PEG-MGF - A pegylated mechano-growth-factor variant. Long-standing presence in performance research discussion, limited published human data.

For anyone tracking this space, that list is more useful than the July recap. It tells you which compounds will generate the next wave of headlines, the next wave of misinformation, and the next wave of "is it legal now" questions.

The committee question worth raising

Coverage of the July meeting in the clinical trade press has raised a question about the committee itself. The reconstituted PCAC drew conflict-of-interest scrutiny, with analysts noting increased representation from clinicians and businesses involved in prescribing, producing or promoting peptides.

We are a peptide company. It would be easy for us to leave that detail out, because the vote went the way the industry wanted. We are including it because a favorable outcome from a panel whose composition is being questioned is a weaker signal than a favorable outcome from an unquestioned one - and because if the reverse were true, we would want to know.

FDA staff, for their part, cited short and underpowered studies as insufficient to establish safety and effectiveness for the proposed uses. That criticism does not disappear because a committee voted the other way. It is the same criticism that a proposed rule will have to address.

Why none of this changes what we sell

BioPure Peptides supplies research materials. Our products are intended strictly for in-vitro laboratory and research use. They are not for human or animal consumption, and no outcome of the 503A process changes that.

This is worth stating plainly, because the reclassification story has already been misused. Sellers have implied that sourcing restrictions were lifted, that research-chemical purchases became legitimate therapeutic purchases, or that a favorable advisory vote is a form of endorsement. None of that is true. The compounding pathway, if it ever opens, runs through a licensed pharmacy and a prescription written by a clinician for a specific patient. It does not run through an online vendor, and it does not run through us.

We do not publish protocols, and we do not discuss human use. When customers ask us what to do with a compound, the honest answer is that we cannot tell them - not because we are being evasive, but because a supplier that answers that question has stopped being a research supplier. Handling, storage and reconstitution references for laboratory work are maintained separately at peptideorders.com.

What actually determines quality - and it isn't the docket

Regardless of how the 503A process resolves, the variable that matters for research material is the same one it has always been: where the compound was made and what documentation follows it.

That variable got more consequential this year, not less. In May 2026, FDA expanded Import Alert 66-40 to cover 38 additional foreign manufacturers of peptide active pharmaceutical ingredients, spanning facilities in China, India and South Korea. Those manufacturers account for an estimated 30% of injectable peptide API entering the United States annually, with the largest concentration - 22 facilities - in China's Zhejiang and Jiangsu provinces. Products from flagged facilities are subject to detention at the border without physical examination.

The inspection findings behind that action are the part worth reading twice. Investigators documented recurring deficiencies in three areas: sterility assurance systems, heavy-metal contamination testing of raw peptide powders, and the integrity of Certificate of Analysis records. That last one deserves emphasis. A COA is only worth what the facility that issued it is worth.

BioPure Peptides manufactures in the United States, in a WHO/GMP and ISO 9001 certified facility, and tests to greater than 99% purity. Documentation is available on request, and our team in Chandler, Arizona can discuss specifications rather than just shipping. If you want the longer version of why domestic manufacturing costs more, we have written it up: why premium USA-made peptides cost more.

Frequently asked questions

Did the FDA approve BPC-157 in 2026?

No. An advisory committee recommended it for the 503A Bulks List. That is not FDA drug approval, and it is not the same as being added to the list. As of this writing, no formal listing has occurred.

Are BPC-157, TB-500 or Semax legal to buy for personal use now?

No. The July votes did not change the legal status of any substance. Materials sold by research suppliers, including us, remain research use only.

What is the difference between Category 1, Category 2 and the 503A Bulks List?

Category 1 and Category 2 are interim designations FDA applies to nominated bulk substances while it evaluates them. The 503A Bulks List is the formal regulation - 21 CFR 216.23 - naming substances that may be used in patient-specific compounding. Removal from Category 2 does not place a substance in Category 1, and neither one is the same as being on the Bulks List.

When will FDA make a final decision?

There is no published date. The process requires proposed rulemaking, a public comment period and a final rule. Prior 503A cycles suggest this takes many months.

Which peptides are reviewed next?

FDA has signaled a second review covering LL-37, GHK-Cu, dihexa acetate, Melanotan II and PEG-MGF, expected before the end of February.

Questions we will answer

If you are evaluating a supplier, ask where the material was synthesized, which lab produced the COA, and whether the stated purity is HPLC purity or net peptide content. We will answer all three. Call (888) 745-1505 or reach us through our contact page.

What we will not answer is what to do with the material after it arrives. That is the line, and we intend to keep standing on it regardless of what the docket says.

All products sold by BioPure Peptides are intended strictly for in-vitro laboratory and research use only. They are not for human or animal consumption. These statements have not been evaluated by the U.S. Food and Drug Administration, and these products are not intended to diagnose, treat, cure, or prevent any disease.